The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia

Shinya Hiramitsu, Yoshiaki Ishiguro, Hiroyuki Matsuyama, Kenji Yamada, Kazuo Kato, Manji Noba, Akihisa Uemura, Satoshi Yoshida, Yoshiro Matsubara, Atsushi Kani, Kazuo Hasegawa, Hitoshi Hishida, Yukio Ozaki

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Aim: To demonstrate the clinical benefit of inhibiting intestinal cholesterol absorption, we evaluated the effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis, lipid and glucose metabolism, and markers of obesity and inflammation. Methods: A total of 120 patients with dyslipidemia (46 men; mean age 66.5 years), who had not achieved the low density lipoprotein cholesterol (LDL-C) goal recommended by the Japan Atherosclerosis Society Guideline despite diet and exercise or any statin therapy, were enrolled and additionally treated with ezetimibe (10 mg/day) for 12 weeks. Results: Compared to the baseline, LDL-C was reduced by 19.2% (p<0.001) after ezetimibe monotherapy and by 24.7% (p<0.001) after co-administration with ezetimibe and any statin. Ezetimibe therapy decreased cholesterol absorption markers and increased a cholesterol synthesis marker. Treatment with ezetimibe reduced the fasting serum insulin level (p<0.05) and HbA1c (p<0.05), increased serum adiponectin (p<0.01), and showed a significant decrease of high-sensitive C-reactive protein (hsCRP, p<0.01). No adverse events occurred during the study. Conclusion: Thus, cholesterol absorption inhibition by ezetimibe is an important therapeutic strategy since LDL-C and cholesterol absorption markers had a positive correlation. Ezetimibe not only reduced the serum LDL-C level but also improved glucose metabolism as well as obesity and inflammation markers. These findings support the benefit of ezetimibe as a new option for the treatment of dyslipidemia.

Original languageEnglish
Pages (from-to)106-114
Number of pages9
JournalJournal of atherosclerosis and thrombosis
Volume17
Issue number1
DOIs
Publication statusPublished - 01-01-2010

Fingerprint

Dyslipidemias
Biomarkers
Cholesterol
LDL Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Metabolism
Obesity
Serum
Inflammation
Therapeutics
Ezetimibe
Glucose
Adiponectin
Intestinal Absorption
Nutrition
Lipid Metabolism
C-Reactive Protein
Fasting
Atherosclerosis
Japan

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine
  • Biochemistry, medical

Cite this

Hiramitsu, Shinya ; Ishiguro, Yoshiaki ; Matsuyama, Hiroyuki ; Yamada, Kenji ; Kato, Kazuo ; Noba, Manji ; Uemura, Akihisa ; Yoshida, Satoshi ; Matsubara, Yoshiro ; Kani, Atsushi ; Hasegawa, Kazuo ; Hishida, Hitoshi ; Ozaki, Yukio. / The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. In: Journal of atherosclerosis and thrombosis. 2010 ; Vol. 17, No. 1. pp. 106-114.
@article{5b9f6429011a40c8bf404f8f3791af7d,
title = "The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia",
abstract = "Aim: To demonstrate the clinical benefit of inhibiting intestinal cholesterol absorption, we evaluated the effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis, lipid and glucose metabolism, and markers of obesity and inflammation. Methods: A total of 120 patients with dyslipidemia (46 men; mean age 66.5 years), who had not achieved the low density lipoprotein cholesterol (LDL-C) goal recommended by the Japan Atherosclerosis Society Guideline despite diet and exercise or any statin therapy, were enrolled and additionally treated with ezetimibe (10 mg/day) for 12 weeks. Results: Compared to the baseline, LDL-C was reduced by 19.2{\%} (p<0.001) after ezetimibe monotherapy and by 24.7{\%} (p<0.001) after co-administration with ezetimibe and any statin. Ezetimibe therapy decreased cholesterol absorption markers and increased a cholesterol synthesis marker. Treatment with ezetimibe reduced the fasting serum insulin level (p<0.05) and HbA1c (p<0.05), increased serum adiponectin (p<0.01), and showed a significant decrease of high-sensitive C-reactive protein (hsCRP, p<0.01). No adverse events occurred during the study. Conclusion: Thus, cholesterol absorption inhibition by ezetimibe is an important therapeutic strategy since LDL-C and cholesterol absorption markers had a positive correlation. Ezetimibe not only reduced the serum LDL-C level but also improved glucose metabolism as well as obesity and inflammation markers. These findings support the benefit of ezetimibe as a new option for the treatment of dyslipidemia.",
author = "Shinya Hiramitsu and Yoshiaki Ishiguro and Hiroyuki Matsuyama and Kenji Yamada and Kazuo Kato and Manji Noba and Akihisa Uemura and Satoshi Yoshida and Yoshiro Matsubara and Atsushi Kani and Kazuo Hasegawa and Hitoshi Hishida and Yukio Ozaki",
year = "2010",
month = "1",
day = "1",
doi = "10.5551/jat.1578",
language = "English",
volume = "17",
pages = "106--114",
journal = "Journal of Atherosclerosis and Thrombosis",
issn = "1340-3478",
publisher = "Japan Atherosclerosis Society",
number = "1",

}

Hiramitsu, S, Ishiguro, Y, Matsuyama, H, Yamada, K, Kato, K, Noba, M, Uemura, A, Yoshida, S, Matsubara, Y, Kani, A, Hasegawa, K, Hishida, H & Ozaki, Y 2010, 'The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia', Journal of atherosclerosis and thrombosis, vol. 17, no. 1, pp. 106-114. https://doi.org/10.5551/jat.1578

The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. / Hiramitsu, Shinya; Ishiguro, Yoshiaki; Matsuyama, Hiroyuki; Yamada, Kenji; Kato, Kazuo; Noba, Manji; Uemura, Akihisa; Yoshida, Satoshi; Matsubara, Yoshiro; Kani, Atsushi; Hasegawa, Kazuo; Hishida, Hitoshi; Ozaki, Yukio.

In: Journal of atherosclerosis and thrombosis, Vol. 17, No. 1, 01.01.2010, p. 106-114.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia

AU - Hiramitsu, Shinya

AU - Ishiguro, Yoshiaki

AU - Matsuyama, Hiroyuki

AU - Yamada, Kenji

AU - Kato, Kazuo

AU - Noba, Manji

AU - Uemura, Akihisa

AU - Yoshida, Satoshi

AU - Matsubara, Yoshiro

AU - Kani, Atsushi

AU - Hasegawa, Kazuo

AU - Hishida, Hitoshi

AU - Ozaki, Yukio

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Aim: To demonstrate the clinical benefit of inhibiting intestinal cholesterol absorption, we evaluated the effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis, lipid and glucose metabolism, and markers of obesity and inflammation. Methods: A total of 120 patients with dyslipidemia (46 men; mean age 66.5 years), who had not achieved the low density lipoprotein cholesterol (LDL-C) goal recommended by the Japan Atherosclerosis Society Guideline despite diet and exercise or any statin therapy, were enrolled and additionally treated with ezetimibe (10 mg/day) for 12 weeks. Results: Compared to the baseline, LDL-C was reduced by 19.2% (p<0.001) after ezetimibe monotherapy and by 24.7% (p<0.001) after co-administration with ezetimibe and any statin. Ezetimibe therapy decreased cholesterol absorption markers and increased a cholesterol synthesis marker. Treatment with ezetimibe reduced the fasting serum insulin level (p<0.05) and HbA1c (p<0.05), increased serum adiponectin (p<0.01), and showed a significant decrease of high-sensitive C-reactive protein (hsCRP, p<0.01). No adverse events occurred during the study. Conclusion: Thus, cholesterol absorption inhibition by ezetimibe is an important therapeutic strategy since LDL-C and cholesterol absorption markers had a positive correlation. Ezetimibe not only reduced the serum LDL-C level but also improved glucose metabolism as well as obesity and inflammation markers. These findings support the benefit of ezetimibe as a new option for the treatment of dyslipidemia.

AB - Aim: To demonstrate the clinical benefit of inhibiting intestinal cholesterol absorption, we evaluated the effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis, lipid and glucose metabolism, and markers of obesity and inflammation. Methods: A total of 120 patients with dyslipidemia (46 men; mean age 66.5 years), who had not achieved the low density lipoprotein cholesterol (LDL-C) goal recommended by the Japan Atherosclerosis Society Guideline despite diet and exercise or any statin therapy, were enrolled and additionally treated with ezetimibe (10 mg/day) for 12 weeks. Results: Compared to the baseline, LDL-C was reduced by 19.2% (p<0.001) after ezetimibe monotherapy and by 24.7% (p<0.001) after co-administration with ezetimibe and any statin. Ezetimibe therapy decreased cholesterol absorption markers and increased a cholesterol synthesis marker. Treatment with ezetimibe reduced the fasting serum insulin level (p<0.05) and HbA1c (p<0.05), increased serum adiponectin (p<0.01), and showed a significant decrease of high-sensitive C-reactive protein (hsCRP, p<0.01). No adverse events occurred during the study. Conclusion: Thus, cholesterol absorption inhibition by ezetimibe is an important therapeutic strategy since LDL-C and cholesterol absorption markers had a positive correlation. Ezetimibe not only reduced the serum LDL-C level but also improved glucose metabolism as well as obesity and inflammation markers. These findings support the benefit of ezetimibe as a new option for the treatment of dyslipidemia.

UR - http://www.scopus.com/inward/record.url?scp=76249107102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76249107102&partnerID=8YFLogxK

U2 - 10.5551/jat.1578

DO - 10.5551/jat.1578

M3 - Article

VL - 17

SP - 106

EP - 114

JO - Journal of Atherosclerosis and Thrombosis

JF - Journal of Atherosclerosis and Thrombosis

SN - 1340-3478

IS - 1

ER -